1. FDA establishes a CBER Safety Council for postmarketing oversight of biologics
FDA announced on 19 November the CBER Safety Council, a governance body within the Center for Biologics Evaluation and Research that replaces the long-standing Safety Working Group and is separate from the product offices that conduct premarket review, reporting directly to the CBER Director. The Council will review postmarketing safety signals across all CBER-regulated products, including vaccines, cell and gene therapies and blood products, conduct structured benefit-risk assessments, and recommend actions such as safety labelling changes, REMS, safety-related postmarketing requirements and safety-related market withdrawals, with the Center Director remaining responsible for regulatory action. FDA says the Council will draw on the Division of Pharmacovigilance and other CBER analytic units, keep formal surveillance partnerships with Sentinel, VAERS and the CDC Vaccine Safety Datalink, and publish safety communications promptly after significant safety determinations, with the evidence behind each decision. For safety teams at CBER sponsors, the change, effective 19 November, signals a more structured and visible route from signal to regulatory action, and further details on membership and operating procedures are still to be published. FDA, 19 Nov 2026
2. Two US rare-disease approvals with significant safety conditions: cemdisiran (Livsayis) and venglustat (Infilbray)
FDA approved on 18 November Livsayis (cemdisiran), a C5-directed siRNA given subcutaneously every three months for adults with anti-AChR antibody-positive generalised myasthenia gravis, with a boxed warning for serious meningococcal infections and availability only through the Livsayis REMS. The REMS requires prescriber enrolment and counselling, meningococcal vaccination (serogroups A, C, W, Y and B) at least two weeks before the first dose or antibacterial prophylaxis if treatment must start urgently, certified dispensing sites, and a Patient Safety Card carried during treatment and for 12 months after the last dose. On the same day FDA approved Infilbray (venglustat) tablets for the neurological manifestations of Type 3 Gaucher disease, whose labelling carries warnings for suicidal ideation and behaviour (with assessment of psychiatric risk before treatment and monitoring during it), lens opacification in paediatric patients based on juvenile rat findings (with annual eye examinations) and embryofetal toxicity. For safety teams, both labels show how class experience and nonclinical findings translate into concrete monitoring requirements, and for Livsayis the 12-month card requirement after the last dose means vaccination status and time since last dose should be captured in infection case reports. Regeneron, 18 Nov 2026, Livsayis prescribing information, Nov 2026, FDA, 18 Nov 2026 and Infilbray prescribing information, Nov 2026
3. FDA maintains the clinical hold on xaranetide and requests a rat neurotoxicity study
Argenica Therapeutics disclosed on 19 November that FDA has kept the clinical hold on its IND for xaranetide in acute ischaemic stroke after reviewing the company's complete response submitted on 23 September. According to the company, FDA has requested a GLP nonclinical neurotoxicity study in rats to assess whether xaranetide produces Olney lesions, which FDA noted can arise in rats given high-affinity NMDA channel blockers, to be completed before further human dosing under the IND, and has lowered the permitted clinical plasma exposure limit, requiring a ten-fold margin to the rat no-effect exposure. The company states that no microscopic brain damage has been seen in its nonclinical studies to date, disputes the data behind the revised exposure limit and plans to request a Type A meeting, while continuing regulatory submissions in other jurisdictions. For safety teams, the case shows that mechanism-based class findings can drive nonclinical requirements and dose ceilings before further clinical development, and that exposure margins should be justified on robust toxicokinetic data. Argenica ASX announcement via Kalkine, 19 Nov 2026
4. Health Canada: imported Italian spinal bupivacaine with Italian-only labels during a shortage
Health Canada published on 19 November a health professional risk communication on the exceptional, temporary importation of Italian-authorised BUPISEN iperbarica 7.5 mg/mL (bupivacaine hydrochloride in dextrose) for spinal anaesthesia, to address a shortage of the Canadian product. The strength and route are the same, but the imported ampoule contains 3 mL instead of 2 mL, the label shows the strength as "7,5 mg/ml" without the total amount per ampoule, does not state single-dose or spinal use only, the product has no DIN or barcode that scans in Canadian systems, and the product must not be autoclaved, unlike the Canadian product; the Canadian recommendation against use under 18 years still applies. Health professionals are asked to follow the Canadian product monograph and report serious or unexpected adverse reactions. For safety teams, shortage-driven imports with foreign labelling are a recognised source of medication errors, and reports of wrong dose, wrong route or handling errors should be checked against such imported supplies. Health Canada, 19 Nov 2026
This news brief is for information only and is not medical or regulatory advice. Source links open the original publication in a new tab.
Follow Safety Strategy on LinkedIn (opens in a new tab) for updates. All news briefs · News and articles